Bio Protocol links BIO, veBIO, BioXP, launch access, and BioAgents into a DeSci funding layer, but token value capture still depends on treasury revenue and verified scientific progress.
Investment View
The investment view should track research milestone proof and treasury transparency before assigning too much weight to launch frequency, secondary trading fees, or BioAgents usage.
Bio Protocol has evolved into a DeSci finance layer through V2 launchpad, liquidity engine, and BioAgents, but revenue validation remains early.
Investment View
Investors should focus less on new launches and more on TVL, recurring fees, and onchain validation of scientific IP outcomes.